Insilico Medicine and Bora Pharmaceuticals lreveal plans for an AI-driven biologics manufacturing venture, forecast to be worth over $2.5B.
Insilico Medicine and Taiwan-based CDMO Bora Pharmaceuticals are launching a new company with an AI-driven biologics manufacturing platform in a bid to compete with service …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Red-hot generative AI specialist Insilico Medicine has teamed up with another major biopharma player, this time linking up with…
“We want to be the SpaceX of the pharmaceutical industry,” Alex Zhavoronkov, co-CEO of Insilico Medicine tells Fortune.
Insilico Medicine And SK Biopharmaceuticals Achieved AI-powered Drug Discovery Collaboration Worth Up to 2.5 Billion for…
Takeda and Insilico Medicine sign a $600M AI drug discovery deal, adding to Insilico's growing portfolio of billion-dollar pharma…
The pharma company, first to use generative AI to develop a drug that reached clinical trials, is betting longevity treatments…
Insilico Medicine Announces Collaboration with Takeda to Advance Strategic AI Drug Discovery
